Check for updates

### **OPEN ACCESS**

EDITED BY Jared M. Gollie, United States Department of Veterans Affairs, United States

REVIEWED BY Atefeh Ashabi, Semnan University of Medical Sciences, Iran Lina Johansson, Imperial College London, United Kingdom Maria Serena Lonardo, University of Naples Federico II, Italy

\*CORRESPONDENCE Rongshao Tan ⊠ tanrongshao@126.com

RECEIVED 09 August 2024 ACCEPTED 21 November 2024 PUBLISHED 03 December 2024

### CITATION

Li C, Pan X, Xu S, Hu J, Zhong X, Wen L, Qiu J and Tan R (2024) Handgrip strength is independently associated with physical quality of life in patients undergoing maintenance hemodialysis: a cross-sectional study. *Front. Nutr.* 11:1478209. doi: 10.3389/fnut.2024.1478209

### COPYRIGHT

© 2024 Li, Pan, Xu, Hu, Zhong, Wen, Qiu and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Handgrip strength is independently associated with physical quality of life in patients undergoing maintenance hemodialysis: a cross-sectional study

Chunlei Li<sup>1,2</sup>, Xiangyou Pan<sup>3</sup>, Shilin Xu<sup>3</sup>, Jianguang Hu<sup>3</sup>, Xiaoshi Zhong<sup>3</sup>, Luona Wen<sup>2</sup>, Jingxian Qiu<sup>2</sup> and Rongshao Tan<sup>1,2</sup>\*

<sup>1</sup>Department of Clinical Nutrition, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China, <sup>2</sup>Guangzhou Institute of Disease-Oriented Nutritional Research, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China, <sup>3</sup>Department of Nephrology, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China

**Objective:** We aimed to identify the association between Health-related quality of life (HRQoL) and muscle strength in patients undergoing maintenance hemodialysis (MHD).

**Methods:** In this cross-sectional study from March 2021 to December 2021, 110 MHD patients with a mean age of  $63.9 \pm 13.0$  years and a median dialysis vintage of 25.5 (12.0–52.3) months, were enrolled at a hemodialysis center in Guangzhou city, China. HRQoL was assessed using the Short Form 36 Health Survey (SF-36) and converted into the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The groups were assigned according to the mean score of PCS and MCS, and those with higher PCS/MCS scores (high-PCS/MCS) were compared with those with lower PCS/MCS scores (low-PCS/MCS). Independent factors were evaluated using multivariate analysis. Muscle strength was estimated by handgrip strength (HGS).

**Results:** The mean HGS was  $23.7 \pm 9.60$  kg in men and  $14.3 \pm 5.30$  kg in women. Compared to the high-PCS group, the low-PCS group had older age, higher levels of creatinine, total cholesterol, high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6), and had lower HGS (all p < 0.05). After adjusting for confounding factors in different models, the five-model multivariate binary logistic regression analyses revealed that HGS was the only independent factor in PCS domain, but not in MCS.

**Conclusion:** HGS may be an independent factor of poor HRQoL in MHD patients, particularly in relation to physical health. The management of muscle strength may improve the HRQoL in MHD patients.

**Clinical trial registration:** The study was registered at https://www.chictr.org. cn/ as ChiCTR2100053790.

### KEYWORDS

muscle strength, quality of life, physical health, sarcopenia, maintenance hemodialysis

### Introduction

Maintenance hemodialysis (MHD) serves as a life-sustaining treatment for individuals with end-stage renal disease (ESRD). Although the survival rate of ESRD has improved over time, patients undergoing MHD have a lower quality of life compared to the general population (1). Health-related quality of life (HRQoL) reflects the impact of disease and healthcare on patients' functional status and their subjective perception of life (2), and it is affected by factors such as psychological health, physical state, level of independence, and social relations (3). In MHD patients, studies have shown that HRQoL is a strong and independent predictor of mortality and hospitalization (4-8). Evaluating and analyzing HRQoL in MHD patients is an important objective. Various generic and disease-specific questionnaires have been utilized to evaluate the quality of life in patients with renal disease (9). The Medical Outcomes Study Short Form 36 Health Survey (SF-36) is a widely recognized generic instrument for assessing HRQoL in ESRD patients (2, 10). There are differences in the HRQoL of hemodialysis patients across different countries and regions (11).

As renal function deteriorates, MHD patients experience physical inactivity, malnutrition and muscle wasting, which together make them more prone to sarcopenia (12). Sarcopenia, characterized by a combination of low muscle mass, strength and function, (13) is a condition related to aging with adverse clinical outcomes, including increased mortality rates, diminished mobility, and an elevated risk of falls and fractures (14, 15). Previous studies on older individuals have suggested that muscle strength, rather than muscle mass, influences factors such as quality of life, mortality risk and physical performance (16–18). While sarcopenia has been linked to reduced HRQoL in community-dwelling older adults (19, 20), the impact of sarcopenia and its components, such as muscle strength and muscle mass, on HRQoL in patients undergoing MHD remains underexplored (21–23).

The objective of this cross-sectional study was to examine the relationship between HRQoL and sarcopenic parameters, with a specific focus on muscle strength, in Chinese patients undergoing MHD.

### **Methods**

### Study design and participants

A single-center cross-sectional study was conducted. Patients were recruited from March 2021 to December 2021 in the hemodialysis center of our hospital. This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Guangzhou Red Cross Hospital, Jinan University (No.2021–066-01). The study was registered on the Chinese Clinical Trial Registry (ChiCTR2100053790).<sup>1</sup> Informed consent was obtained from each participant before enrollment.

The inclusion criteria were as follows: (a) dialysis vintage more than 3 months, three times a week, 4 h each session, (b) age 18 years

or older, (c) informed consent. The exclusion criteria were: (a) patients with pacemakers, (b) a history of severe infections, trauma or surgery within the past 3 months, (c) patients with diabetic feet, or amputations, (d) those with physical disabilities or who could not cooperate with the study for other reasons, (e) patients with malignant tumors.

### Health-related quality of life

HRQoL was assessed using the 36-item Short-Form Health Survey (SF-36) (24). This tool is a patient-related questionnaire that generates scores across eight subscales: physical functioning (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), mental health (MH). Each scale is scored from 0 to 100. Two health component summary measures, the Physical Component Summary (PCS) and Mental Component Summary (MCS), were calculated from eight domain subscales for easier and simpler interpretation and analysis (25, 26). A higher score on these summaries indicates better HRQoL. The SF-36 scores use norm-based scoring in which the scale and component summary scores have a mean of 50 and standard deviation of 10 in the US general population. For better international comparability, patients in this study were allocated into two groups based on the mean of 50, which originated from the U.S. population. In each summary component, scores ≥50 were designated as the high-PCS or high-MCS (better HRQoL) group, and the scores <50 was designated as the low-PCS or low MCS (poorer HRQoL) group.

### Handgrip strength

Handgrip strength (HGS) was measured using the BASELINE digital Grip Force Tester (12-0091, Fabrication Enterprises Inc., United States). Measurements were performed on the non-fistula hand before the hemodialysis session. Participants were seated in a straightbacked chair with their feet flat on the floor, their shoulders adducted, and their elbow flexed at 90°. The forearm was kept in a neutral position. The arm should not be supported by the patient, examiner, or by an armrest. The dynamometer was held vertically in line with the forearm. The hand was positioned with the thumb around one side of the handle and the four fingers around the other side. For each patient, measurements were repeated three times and the highest score was used in our analysis. The interval between the three measurements was at least 1 min. Grip strength was read in kilograms (kg) from the outside dial and recorded to the nearest 1 kg on the data entry form. According to the consensus of the Asian Working Group for Sarcopenia (AWGS) (13), low hand grip strength (low-HGS) was defined as HGS <28 kg for men and < 18 kg for women.

# Demographic, clinical and laboratory parameters

Demographic (age, gender), clinical data (dialysis duration, history of diabetes, primary disease) were collected by retrieving medical records and asking the patient directly. Blood samples were

<sup>1</sup> https://www.chictr.org.cn

collected before dialysis sessions for serum dosages of blood urea nitrogen (BUN), creatinine, phosphorus, hemoglobin, albumin, prealbumin, total cholesterol (TC), triglyceride, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), interleukin-1 $\beta$ (IL-1 $\beta$ ), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), transforming growth factor- $\beta$  (TGF- $\beta$ ). The Kt/V was calculated according to Daugirda's formula (27).

### Anthropometric measurement

Dry body weight and height were measured to the nearest 0.01 kg/0.1 cm, and body mass index (BMI) was calculated as dry body weight divided by squared height (kg/m<sup>2</sup>). We also assessed triceps skinfold thick ness (TSF) and mid-upper arm circumference (MAC) after the hemodialysis sessions with the skinfold caliper (Guangdong Xiangshanweihua Corporation Ltd., EH101, China) and a flexible plastic, non-stretchable tape. Mid-arm muscle circumference (MAMC) was calculated using the following equation: (28).

MAMC (cm) = MAC (cm)  $- [TSF(cm) \times \pi]$ .

### Body composition measurement

Whole-body composition was measured using a body composition analyzer (Multiscan 5,000; Bodystat, Isle of Man, United Kingdom) by bioimpedance spectroscopy analysis (BIS). Body fat mass and lean body mass were measured. The equations for calculating appendicular skeletal muscle (ASM) and appendicular skeletal muscle index (ASMI) are according to Adrian's formula (29).

### Sarcopenia criteria

Sarcopenia was diagnosed as low HGS and low ASMI on the basis of the criteria proposed by AWGS (2019): (13) (1) ASMI <7.0 kg/m<sup>2</sup> for men and < 5.7 kg/m<sup>2</sup> for women; (2) HGS <28 kg for men and < 18 kg for women.

### Statistical analysis

Statistical analyses were performed using SPSS version 22.0 statistical software (IBM Corp., Armonk, NY). All variables were tested for normality using the Shapiro–Wilk normality test. Continuous variables with a normal distribution were presented as the mean ± standard deviation, and those with non-normal distribution were described as median (25–75% interquartile range). Categorical variables were presented using percentages. Participants were divided into high-PCS/MCS and low-PCS/MCS groups. Differences between the 2 groups were assessed using a student's t-test, Mann–Whitney U test, or chi-squared test, as appropriate. Normally distributed variables were compared using the t-test. For variables that did not exhibit a normal distribution, the Mann–Whitney U test was utilized. Associations between categorical variables were estimated using the chi-squared test. The two-tailed Fisher exact test was used for dichotomous variables. Variables with *p*-values <0.05 on comparison between the groups were subsequently analyzed

using multivariate logistic regression to identify the independent factors of low-PCS/MCS by using a forward-stepwise method. A two-tailed *p*-value <0.05 was considered to indicate statistical significance.

### Results

# Comparison of clinical characteristics between the high- and low-PCS/MCS groups

Comparison of clinical characteristics between high-and low-PCS/MCS groups are shown in Tables 1, 2. The number of participants in the high-PCS group was smaller than that in the low-PCS group. Compared to the high-PCS group, the low-PCS group had older age, higher levels of total cholesterol, high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6), as well as lower levels of creatinine and reduced hand grip strength (all p < 0.05; Table 1). There were no differences in gender, BMI, dialysis vintage, BUN, kt/V, hemoglobin, albumin and prealbumin between the high-and low-PCS groups (Table 1). Only total cholesterol levels showed significant differences between the low-MCS and high-MCS groups. Compared to the high-MCS group, the low-MCS group had lower levels of total cholesterol (p = 0.034; Table 2).

### Characteristics of study participants

The screening process is presented in Figure 1. Demographic, biochemical and anthropometric parameters of the study participants are shown in Table 3. A total of 110 patients (70 men and 40 women) undergoing MHD were enrolled in the study, with a mean age of  $63.9 \pm 13.0$  years and a median dialysis vintage of 25.5 months (12.0–52.3 months), and 56 of them had diabetes (50.9%). The average BMI was  $23.0 \pm 3.60$  kg/m<sup>2</sup>, the mean HGS was  $23.7 \pm 9.60$  kg in men and  $14.3 \pm 5.30$  kg in women. According to the AWGS criteria, 80% of the participants were diagnosed as low-HGS, 35.5% have low-ASMI, and 35.5% were suffering from sarcopenia. The mean PCS score was  $43.8 \pm 9.50$ , and the mean MCS score was  $57.3 \pm 8.80$ .

# Associations between HGS and PCS in patients undergoing MHD

After adjustment for age, sex, fat mass, ASMI, creatinine, TC, hsCRP, and albumin, the five-model multivariate binary logistic regression analyses showed that lower HGS levels and HGS <28 kg for men and < 18 kg for women were both independently associated with lower PCS scores in patients undergoing MHD (p < 0.05; Table 4). Since the univariate analysis of HGS and MCS scores did not show statistical significance (Table 2), subsequent binary logistics regression analysis was not conducted in MCS.

### Discussion

To our knowledge, this study is the first to investigate the relationship between HRQoL and sarcopenic parameters, with a

TABLE 1 Comparison of clinical characteristics of the high-and low-PCS groups.

Age (years)58.5 ± 12.466.6 ± 12.50.0021Women (n (%))12 (33.3)28 (37.8)0.454BM (kg/m²)22.2 ± 2.7023.4 ± .000.124Dialysis vintage (month)55.0 (11.5 - 67.5)24.0 (12.0 - 50.3)0.456Gause of end -stage removed (sizea en (%))11 (30.6)28 (37.8)0.504Diabetic nephropathy11 (30.6)28 (37.8)0.504Phypertensive7 (19.4)7 (9.50)7 (19.4)rephropathy7 (19.4)7 (9.50)1.001Other*4 (11.1)7 (9.50)1.001Diabetic nephropathy14 (38.9)30 (40.5)0.072Diabetis mellitus (n%)1.40 (1.20 - 150)300 (40.5)0.075Diabetes mellitus (n%)1.075 ± 313948 ± 2780.034Kt/V1.40 (1.20 - 150)1.301 (1.20 - 160)0.621Serum phosphorus2.10 (1.70 - 2.60)2.20 (1.80 - 2.60)0.821Mimoil/J95.3 ± 17.497.7 ± 1.6.0.402Albunin (g/L)3.80 ± 2.903.01 (4.50 + 10.4)0.021Albunin (g/L)1.07 ± 1.001.20 ± 1.600.021Frealburin (mg/L)1.07 ± 1.001.20 ± 1.600.021Albunin (g/L)1.01 ± 1.001.02 ± 1.600.021Frealpertin (mg/L)1.02 ± 1.600.0210.021Albunin (g/L)1.02 ± 1.600.0210.021Albunin (g/L)1.02 ± 1.600.0210.021Frealpertin (mg/L)1.02 ± 1.600.0210.021Albunin (g/L)	Variables	High-PCS <sup>†</sup> n = 36	Low-PCS <sup>†</sup> <i>n</i> = 74	$ ho^{\dagger}$
BMI (kg/m²)22.2 ± 2.7023.4 ± 4.000.124Dialysis vintage (month)35.0 (11.5-67.5)24.0 (12.0-50.3)0.456Cause of end-stage renal disease [n (%)]11 (30.6)28 (37.8).Diabetic nephropathy11 (30.6)28 (37.8).Hypertensive nephropathy7 (19.4)7 (9.50).Polycystic kidney disease2 (5.60)2 (2.70).Unknown causes12 (33.3)30 (40.5).Other <sup>4</sup> 4 (11.1)7 (9.50).Diabetes mellitus [n (%)]14 (38.9)42 (56.8)0.079BUN (mmol/L)29.3 (25.0-32.7)26.7 (22.1-32.0)0.055Creatinine (µmol/L)1.075 ± 313948 ± 2780.034Kt/V1.40 (1.20-1.50)1.30 (1.20-1.60)0.672Serum phosphorus (µmonl/L)2.10 (1.70-2.60)3.20 (1.80-2.60)0.6321Hemoglobin (g/L)95.3 ± 17.497.7 ± 16.60.026Albumin (g/L)347 ± 60.73.21 ± 69.70.052Triglyceride (mmol/L)1.70 ± 1.003.20 ± 1.800.021Indacholesterol (mmol/L)4.10 ± 1.004.60 ± 1.100.021Inda (chog/mL)5.00 (5.00-7.20)9.40 (5.01-6.00)0.022Inda (pg/mL)1.23 ± (1.77-1.70)14.3 (1.25-16.5)0.402Inda (pg/mL)1.22 (1.11)1.43 (1.25-16.5)0.402Inda (chog)1.22 (1.11)1.43 (1.25-16.5)0.402Inda (pg/mL)1.23 ± 0.021.1020.424Inda (pg/mL)1.23 ± 0.02 <td>Age (years)</td> <td><math display="block">58.5 \pm 12.4</math></td> <td><math display="block">66.5 \pm 12.5</math></td> <td>0.002</td>	Age (years)	$58.5 \pm 12.4$	$66.5 \pm 12.5$	0.002
Dialysis vintage (months)35.0 (11.5-67.5)24.0 (12.0-50.3)0.456Cause of end-stage renal disease [n (%)]11 (30.6)28 (37.8)Diabetic nephropathy11 (30.6)28 (37.8)Hypertensive nephropathy7 (19.4)7 (9.50)Polycystic kidney disease2 (5.60)2 (2.70)Unknown causes12 (33.3)30 (40.5)Diabetes mellitus [n (%)]14 (38.9)42 (56.8)0.079BUN (mmol/L)29.3 (25.0-32.7)26.7 (22.1-32.0)0.657Creatinine (µmol/L)1.075 ± 313948 ± 2780.034Kt/V1.40 (1.20-1.50)1.30 (1.20-1.60)0.821Greum phosphorus (mmol/L)2.10 (1.70-2.60)2.20 (1.80-2.60)0.821Hemoglobin (g/L)95.3 ± 17.497.7 ± 16.60.4070Albumin (g/L)38.0 ± 2.9036.7 ± 3.300.065Triglyceride (mmol/L)1.70 ± 1.002.20 ± 1.800.0131Total cholesterol (mmol/L)4.10 ± 1.004.60 ± 1.100.021In-G (pg/mL)5.00 (5.00-7.20)5.00 (5.00-7.50)0.022In-G (pg/mL)1.28 (11.7-17.0)14.3 (12.5-1.65.90.464TGF-β (pg/mL)179 (1.00-68017.9 ± 8.400.041In-Ge (pg/mL)179 (1.00-68017.9 ± 8.400.031In-G (pg/mL)22 (61.1)66 (89.2)0.013In-Ge (pg/mL)1.79 (1.00-68017.9 ± 8.400.384In-Ge (pg/mL)1.79 (1.00-68017.9 ± 3.500.383In-	Women [n (%)]	12 (33.3)	28 (37.8)	0.645
Cause of end-stage renal disease [n (%)]Cause of end-stage renal disease [n (%)]Cause of end-stage renal disease [n (%)]Cause of end-stage renal diseaseCause of end-stage renal<	BMI (kg/m <sup>2</sup> )	$22.2\pm2.70$	$23.4\pm4.00$	0.124
disease [n (%)]0.504Diabetic nephropathy11 (30.6)28 (37.8)Hypertensive nephropathy7 (19.4)7 (9.50)Polycystic kidney disease2 (5.60)2 (2.70)Unknown causes12 (33.3)30 (40.5)Unknown causes12 (33.3)30 (40.5)Other <sup>3</sup> 4 (11.1)7 (9.50)Diabetes mellitus [n (%)]14 (38.9)42 (56.8)Diabetes mellitus [n (%)]14 (38.9)42 (56.8)Creatinine (µmol/L)1,075 ± 313948 ± 278K/V1.40 (1.20-1.50)1.30 (1.20-1.60)Serum phosphorus (mmol/L)2.10 (1.70-2.60)2.20 (1.80-2.60)Memoglobin (g/L)95.3 ± 17.497.7 ± 16.6Albumin (g/L)38.0 ± 2.9036.7 ± 3.30Albumin (g/L)347 ± 60.7321 ± 69.7Albumin (mg/L)1.70 ± 1.004.60 ± 1.10Mond/L1.70 ± 1.004.60 ± 1.10Migle (mmol/L)2.10 (1.00-7.60)4.30 (1.70-8.70)Albumin (mg/L)5.00 (5.00-7.20)5.00 (5.00-7.50)Migle (mmol/L)5.00 (5.00-7.20)5.00 (5.00-7.50)Migle (mmol/L)12.8 (11.7-17.00)14.3 (12.5-16.5)Migle (mg/mL)12.8 (11.7-17.00)14.3 (12.5-16.5)Migle (mg/mL)22 (61.1)66 (89.2)Migle (mg/mL)22 (61.1)66 (89.2)Migle (mg/mL)22 (61.1)66 (89.2)Migle (mg/mL)22 (61.1)66 (89.2)Migle (mg/mL)21.3 ± 3.0021.9 ± 3.50Migle (mg/mL)22 (61.1)66 (89.2)	Dialysis vintage (months)	35.0 (11.5-67.5)	24.0 (12.0-50.3)	0.456
Hypertensive nephropathy $7 (19.4)$ $7 (9.50)$ $7 (9.50)$ Polycystic kidney disease $2 (5.60)$ $2 (2.70)$ $2 (2.70)$ Unknown causes $12 (33.3)$ $30 (40.5)$ $30 (40.5)$ Other <sup>5</sup> $4 (11.1)$ $7 (9.50)$ $2 (5.60)$ $2 (2.70)$ Diabetes mellitus [n (%)] $14 (38.9)$ $42 (56.8)$ $0.079$ BUN (mmol/L) $29.3 (25.0 - 32.7)$ $26.7 (22.1 - 32.0)$ $0.055$ Creatinine (µmol/L) $1.075 \pm 313$ $948 \pm 278$ $0.034$ Kt/V $1.40 (1.20 - 1.50)$ $1.30 (1.20 - 1.60)$ $0.679$ Serum phosphorus (mmol/L) $2.10 (1.70 - 2.60)$ $2.20 (1.80 - 2.60)$ $0.821$ Hemoglobin (g/L) $95.3 \pm 17.4$ $97.7 \pm 16.6$ $0.470$ Albumin (g/L) $347 \pm 60.7$ $321 \pm 69.7$ $0.058$ Triglyceride (mmol/L) $1.70 \pm 1.00$ $2.20 \pm 1.80$ $0.113$ Total cholesterol (mmol/L) $4.10 \pm 1.00$ $4.60 \pm 1.10$ $0.021$ hsCRP (mg/L) $2.10 (1.00 - 7.60)$ $4.30 (1.70 - 8.70)$ $0.024$ IL- $\beta$ (pg/mL) $5.00 (5.00 - 7.20)$ $5.00 (5.00 - 7.50)$ $0.672$ IL- $\beta$ (pg/mL) $12.8 (11.7 - 17.0)$ $14.3 (12.5 - 16.5)$ $0.469$ TOF- $\alpha$ (pg/mL) $22 (61.1)$ $66 (89.2)$ $0.001$ IL- $\beta$ (pg/mL) $22 (61.1)$ $66 (89.2)$ $0.383$ Lean mass (kg) $13.4 \pm 4.80$ $16.8 \pm 6.60$ $0.008$ IL- $\beta$ (mass (kg) $13.6 \pm 4.100$ $16.8 \pm 6.60$ $0.008$	, i i i i i i i i i i i i i i i i i i i			0.504
nephropathy         7 (19.4)         7 (9.50)         Image: Constant of the sector of the	Diabetic nephropathy	11 (30.6)	28 (37.8)	
Polycystic kidney disease2 (5.60)2 (2.70)IPolycystic kidney disease2 (5.60)2 (2.70)IUnknown causes12 (33.3)30 (40.5)IOther <sup>3</sup> 4 (11.1)7 (9.50)IDiabetes mellitus [n (%)]14 (38.9)42 (56.8)0.079BUN (mmol/L)29.3 (25.0-32.7)26.7 (22.1-32.0)0.055Creatinine (µmol/L)1,075 $\pm$ 313948 $\pm$ 2780.034Kt/V1.40 (1.20-1.50)1.30 (1.20-1.60)0.679Serum phosphorus2.10 (1.70-2.60)2.20 (1.80-2.60)0.821(mmol/L)95.3 $\pm$ 17.497.7 $\pm$ 16.60.470Albumin (g/L)38.0 $\pm$ 2.9036.7 $\pm$ 3.300.065Prealbumin (mg/L)347 $\pm$ 60.7321 $\pm$ 69.70.058Triglyceride (mmol/L)1.70 $\pm$ 1.002.20 $\pm$ 1.800.113Total cholesterol	Hypertensive			
Unknown causes12 (33.3)30 (40.5)Image: constraint of the sector of the	nephropathy	7 (19.4)	7 (9.50)	
Other*4 (11.1)7 (9.50)Diabetes mellitus [n (%)]14 (38.9)42 (56.8)0.079BUN (mmol/L)29.3 (25.0-32.7)26.7 (22.1-32.0)0.055Creatinine (µmol/L)1,075 ± 313948 ± 2780.034Kt/V1.40 (1.20-1.50)1.30 (1.20-1.60)0.679Serum phosphorus (mmol/L)2.10 (1.70-2.60)2.20 (1.80-2.60)0.821Hemoglobin (g/L)95.3 ± 17.497.7 ± 16.60.470Albumin (g/L)38.0 ± 2.9036.7 ± 3.300.065Prealbumin (mg/L)347 ± 60.7321 ± 69.70.058Triglyceride (mmol/L)1.70 ± 1.002.20 ± 1.800.113Total cholesterol (mmol/L)4.10 ± 1.004.60 ± 1.100.021hsCRP (mg/L)2.10 (1.00-7.60)4.30 (1.70-8.70)0.024IL-6 (pg/mL)5.00 (5.00-7.20)5.00 (5.00-7.50)0.962TNF- $\alpha$ (pg/mL)172 (1.00-680)172 (42.2-460)0.872TGF- $\beta$ (pg/mL)179 (1.00-680)17.9 ± 8.40<0.001	Polycystic kidney disease	2 (5.60)	2 (2.70)	
Diabetes mellitus [n (%)]14 (38.9)42 (56.8)0.079BUN (mmol/L)29.3 (25.0-32.7)26.7 (22.1-32.0)0.055Creatinine (µmol/L)1,075 ± 313948 ± 2780.034Kt/V1.40 (1.20-1.50)1.30 (1.20-1.60)0.679Serum phosphorus (mmol/L)2.10 (1.70-2.60)2.20 (1.80-2.60)0.821Hemoglobin (g/L)95.3 ± 17.497.7 ± 16.60.470Albumin (g/L)38.0 ± 2.9036.7 ± 3.300.065Prealbumin (mg/L)347 ± 60.7321 ± 69.70.058Triglyceride (mmol/L)1.70 ± 1.002.20 ± 1.800.113Total cholesterol (mmol/L)4.10 ± 1.004.60 ± 1.100.021hsCRP (mg/L)2.10 (1.00-7.60)4.30 (1.70-8.70)0.024IL-6 (pg/mL)5.00 (5.00-7.20)5.00 (5.00-7.50)0.962TNF- $\alpha$ (pg/mL)12.8 (11.7-17.0)14.3 (12.5-16.5)0.469TGF- $\beta$ (pg/mL)179 (1.00-680)172 (42.2-460)0.872HGS (kg)24.8 ± 9.8017.9 ± 8.40<0.001	Unknown causes	12 (33.3)	30 (40.5)	
BUN (mmol/L)29.3 (25.0-32.7)26.7 (22.1-32.0)0.055Creatinine (µmol/L)1,075 ± 313948 ± 2780.034Kt/V1.40 (1.20-1.50)1.30 (1.20-1.60)0.679Serum phosphorus (mmol/L)2.10 (1.70-2.60)2.20 (1.80-2.60)0.821Hemoglobin (g/L)95.3 ± 17.497.7 ± 16.60.470Albumin (g/L)38.0 ± 2.9036.7 ± 3.300.065Prealbumin (mg/L)347 ± 60.7321 ± 69.70.058Triglyceride (mmol/L)1.70 ± 1.002.20 ± 1.800.113Total cholesterol (mmol/L)4.10 ± 1.004.60 ± 1.100.021hsCRP (mg/L)2.10 (1.00-7.60)4.30 (1.70-8.70)0.024IL-1 $\beta$ (pg/mL)5.00 (5.00-7.20)5.00 (5.00-7.50)0.962TNF- $\alpha$ (pg/mL)12.8 (11.7-17.0)14.3 (12.5-16.5)0.469TGF- $\beta$ (pg/mL)179 (1.00-680)172 (42.2-460)0.872HGS (kg)24.8 ± 9.8017.9 ± 8.40<0.001	Other <sup>§</sup>	4 (11.1)	7 (9.50)	
Creatinine (µmol/L) $1,075 \pm 313$ $948 \pm 278$ $0.034$ Kt/V $1.40 (1.20-1.50)$ $1.30 (1.20-1.60)$ $0.679$ Serum phosphorus (mmol/L) $2.10 (1.70-2.60)$ $2.20 (1.80-2.60)$ $0.821$ Hemoglobin (g/L) $95.3 \pm 17.4$ $97.7 \pm 16.6$ $0.470$ Albumin (g/L) $38.0 \pm 2.90$ $36.7 \pm 3.30$ $0.065$ Prealbumin (mg/L) $347 \pm 60.7$ $321 \pm 69.7$ $0.058$ Triglyceride (mmol/L) $1.70 \pm 1.00$ $2.20 \pm 1.80$ $0.113$ Total cholesterol (mmol/L) $4.10 \pm 1.00$ $4.60 \pm 1.10$ $0.021$ hsCRP (mg/L) $2.10 (1.00-7.60)$ $4.30 (1.70-8.70)$ $0.024$ IL-6 (pg/mL) $5.00 (5.00-7.20)$ $5.00 (5.00-7.50)$ $0.962$ TNF- $\alpha$ (pg/mL) $12.8 (11.7-17.0)$ $14.3 (12.5-16.5)$ $0.469$ TGF- $\beta$ (pg/mL) $179 (1.00-680)$ $17.9 \pm 8.40$ $<0.001$ Low-HGS [n (%)] $22 (61.1)$ $66 (89.2)$ $0.001$ MAMC (cm) $21.3 \pm 3.00$ $21.9 \pm 3.50$ $0.383$ Lean mass (kg) $13.4 \pm 4.80$ $16.8 \pm 6.60$ $0.008$ ASMI (kg/m <sup>2</sup> ) $6.80 \pm 1.00$ $6.80 \pm 1.20$ $0.752$	Diabetes mellitus [n (%)]	14 (38.9)	42 (56.8)	0.079
Kt/V1.40 (1.20-1.50)1.30 (1.20-1.60)0.679Serum phosphorus (mmol/L)2.10 (1.70-2.60)2.20 (1.80-2.60)0.821Hemoglobin (g/L)95.3 $\pm$ 17.497.7 $\pm$ 16.60.470Albumin (g/L)38.0 $\pm$ 2.9036.7 $\pm$ 3.300.065Prealbumin (mg/L)347 $\pm$ 60.7321 $\pm$ 69.70.058Triglyceride (mmol/L)1.70 $\pm$ 1.002.20 $\pm$ 1.800.113Total cholesterol (mmol/L)4.10 $\pm$ 1.004.60 $\pm$ 1.100.021hsCRP (mg/L)2.10 (1.00-7.60)4.30 (1.70-8.70)0.024IL-6 (pg/mL)6.80 (4.60-10.7)9.40 (6.30-16.5)0.026IL-1 $\beta$ (pg/mL)5.00 (5.00-7.200)5.00 (5.00-7.500)0.962TNF- $\alpha$ (pg/mL)12.8 (11.7-17.0)14.3 (12.5-16.5)0.469TGF- $\beta$ (pg/mL)179 (1.00-680)17.2 (4.2.2-460)0.872HGS (kg)24.8 $\pm$ 9.8017.9 $\pm$ 8.40<0.001	BUN (mmol/L)	29.3 (25.0-32.7)	26.7 (22.1-32.0)	0.055
Serum phosphorus (mmol/L)2.10 (1.70-2.60)2.20 (1.80-2.60)0.821Hemoglobin (g/L)95.3 $\pm$ 17.497.7 $\pm$ 16.60.470Albumin (g/L)38.0 $\pm$ 2.9036.7 $\pm$ 3.300.065Prealbumin (mg/L)347 $\pm$ 60.7321 $\pm$ 69.70.058Triglyceride (mmol/L)1.70 $\pm$ 1.002.20 $\pm$ 1.800.113Total cholesterol (mmol/L)4.10 $\pm$ 1.004.60 $\pm$ 1.100.021hsCRP (mg/L)2.10 (1.00-7.60)4.30 (1.70-8.70)0.024L-6 (pg/mL)6.80 (4.60-10.7)9.40 (6.30-16.5)0.026IL-1 $\beta$ (pg/mL)5.00 (5.00-7.20)5.00 (5.00-7.50)0.962TNF- $\alpha$ (pg/mL)12.8 (11.7-17.0)14.3 (12.5-16.5)0.469TGF- $\beta$ (pg/mL)179 (1.00-680)172 (42.2-460)0.872HGS (kg)24.8 $\pm$ 9.8017.9 $\pm$ 8.40<0.001	Creatinine (µmol/L)	1,075 ± 313	948 ± 278	0.034
Number2.10 (1.70-2.60)2.20 (1.80-2.60)0.821Hemoglobin (g/L)95.3 $\pm$ 17.497.7 $\pm$ 16.60.470Albumin (g/L)38.0 $\pm$ 2.9036.7 $\pm$ 3.300.065Prealbumin (mg/L)347 $\pm$ 60.7321 $\pm$ 69.70.058Triglyceride (mmol/L)1.70 $\pm$ 1.002.20 $\pm$ 1.800.113Total cholesterol (mmol/L)4.10 $\pm$ 1.004.60 $\pm$ 1.100.021hsCRP (mg/L)2.10 (1.00-7.60)4.30 (1.70-8.70)0.024IL-6 (pg/mL)6.80 (4.60-10.7)9.40 (6.30-16.5)0.026IL-1 $\beta$ (pg/mL)5.00 (5.00-7.20)5.00 (5.00-7.50)0.962TNF- $\alpha$ (pg/mL)12.8 (11.7-17.0)14.3 (12.5-16.5)0.469TGF- $\beta$ (pg/mL)179 (1.00-680)17.2 (42.2-460)0.872HGS (kg)24.8 $\pm$ 9.8017.9 $\pm$ 8.40<0.001	Kt/V	1.40 (1.20–1.50)	1.30 (1.20-1.60)	0.679
Albumin (g/L) $38.0 \pm 2.90$ $36.7 \pm 3.30$ 0.065Prealbumin (mg/L) $347 \pm 60.7$ $321 \pm 69.7$ 0.058Triglyceride (mmol/L) $1.70 \pm 1.00$ $2.20 \pm 1.80$ 0.113Total cholesterol (mmol/L) $4.10 \pm 1.00$ $4.60 \pm 1.10$ 0.021hsCRP (mg/L) $2.10 (1.00-7.60)$ $4.30 (1.70-8.70)$ 0.024L-6 (pg/mL) $6.80 (4.60-10.7)$ $9.40 (6.30-16.5)$ 0.026IL-1 $\beta$ (pg/mL) $5.00 (5.00-7.20)$ $5.00 (5.00-7.50)$ 0.962TNF- $\alpha$ (pg/mL) $12.8 (11.7-17.0)$ $14.3 (12.5-16.5)$ 0.469TGF- $\beta$ (pg/mL) $179 (1.00-680)$ $172 (42.2-460)$ 0.872HGS (kg) $24.8 \pm 9.80$ $17.9 \pm 8.40$ <0.001		2.10 (1.70-2.60)	2.20 (1.80-2.60)	0.821
Prealbumin (mg/L) $347 \pm 60.7$ $321 \pm 69.7$ $0.058$ Triglyceride (mmol/L) $1.70 \pm 1.00$ $2.20 \pm 1.80$ $0.113$ Total cholesterol (mmol/L) $4.10 \pm 1.00$ $4.60 \pm 1.10$ $0.021$ hsCRP (mg/L) $2.10 (1.00-7.60)$ $4.30 (1.70-8.70)$ $0.024$ IL-6 (pg/mL) $6.80 (4.60-10.7)$ $9.40 (6.30-16.5)$ $0.026$ IL-1 $\beta$ (pg/mL) $5.00 (5.00-7.20)$ $5.00 (5.00-7.50)$ $0.962$ TNF- $\alpha$ (pg/mL) $12.8 (11.7-17.0)$ $14.3 (12.5-16.5)$ $0.469$ TGF- $\beta$ (pg/mL) $179 (1.00-680)$ $172 (42.2-460)$ $0.872$ HGS (kg) $24.8 \pm 9.80$ $17.9 \pm 8.40$ <0.001	Hemoglobin (g/L)	95.3 ± 17.4	97.7 ± 16.6	0.470
Triglyceride (mmol/L) $1.70 \pm 1.00$ $2.20 \pm 1.80$ $0.113$ Total cholesterol (mmol/L) $4.10 \pm 1.00$ $4.60 \pm 1.10$ $0.021$ hsCRP (mg/L) $2.10 (1.00-7.60)$ $4.30 (1.70-8.70)$ $0.024$ IL-6 (pg/mL) $6.80 (4.60-10.7)$ $9.40 (6.30-16.5)$ $0.026$ IL-1 $\beta$ (pg/mL) $5.00 (5.00-7.20)$ $5.00 (5.00-7.50)$ $0.962$ TNF- $\alpha$ (pg/mL) $12.8 (11.7-17.0)$ $14.3 (12.5-16.5)$ $0.469$ TGF- $\beta$ (pg/mL) $179 (1.00-680)$ $172 (42.2-460)$ $0.872$ HGS (kg) $24.8 \pm 9.80$ $17.9 \pm 8.40$ <0.001	Albumin (g/L)	38.0 ± 2.90	36.7 ± 3.30	0.065
Total cholesterol (mmol/L)4.10 ± 1.004.60 ± 1.100.021hsCRP (mg/L)2.10 (1.00-7.60)4.30 (1.70-8.70)0.024IL-6 (pg/mL)6.80 (4.60-10.7)9.40 (6.30-16.5)0.026IL-1 $\beta$ (pg/mL)5.00 (5.00-7.20)5.00 (5.00-7.50)0.962TNF- $\alpha$ (pg/mL)12.8 (11.7-17.0)14.3 (12.5-16.5)0.469TGF- $\beta$ (pg/mL)179 (1.00-680)172 (42.2-460)0.872HGS (kg)24.8 ± 9.8017.9 ± 8.40<0.001	Prealbumin (mg/L)	347 ± 60.7	321 ± 69.7	0.058
(mmol/L)         4.10 ± 1.00         4.60 ± 1.10         0.021           hsCRP (mg/L)         2.10 (1.00-7.60)         4.30 (1.70-8.70)         0.024           IL-6 (pg/mL)         6.80 (4.60-10.7)         9.40 (6.30-16.5)         0.026           IL-1β (pg/mL)         5.00 (5.00-7.20)         5.00 (5.00-7.50)         0.962           TNF-α (pg/mL)         12.8 (11.7-17.0)         14.3 (12.5-16.5)         0.469           TGF-β (pg/mL)         179 (1.00-680)         172 (42.2-460)         0.872           HGS (kg)         24.8 ± 9.80         17.9 ± 8.40         <0.001	Triglyceride (mmol/L)	$1.70 \pm 1.00$	2.20 ± 1.80	0.113
IL-6 (pg/mL) $6.80 (4.60-10.7)$ $9.40 (6.30-16.5)$ $0.026$ IL-1 $\beta$ (pg/mL) $5.00 (5.00-7.20)$ $5.00 (5.00-7.50)$ $0.962$ TNF- $\alpha$ (pg/mL) $12.8 (11.7-17.0)$ $14.3 (12.5-16.5)$ $0.469$ TGF- $\beta$ (pg/mL) $179 (1.00-680)$ $172 (42.2-460)$ $0.872$ HGS (kg) $24.8 \pm 9.80$ $17.9 \pm 8.40$ $<0.001$ Low-HGS [n (%)] $22 (61.1)$ $66 (89.2)$ $0.001$ MAMC (cm) $21.3 \pm 3.00$ $21.9 \pm 3.50$ $0.383$ Lean mass (kg) $13.4 \pm 4.80$ $16.8 \pm 6.60$ $0.008$ ASMI (kg/m <sup>2</sup> ) $6.80 \pm 1.00$ $6.80 \pm 1.20$ $0.752$		4.10 ± 1.00	4.60 ± 1.10	0.021
IL-1 $\beta$ (pg/mL)         5.00 (5.00-7.20)         5.00 (5.00-7.50)         0.962           TNF- $\alpha$ (pg/mL)         12.8 (11.7-17.0)         14.3 (12.5-16.5)         0.469           TGF- $\beta$ (pg/mL)         179 (1.00-680)         172 (42.2-460)         0.872           HGS (kg)         24.8 ± 9.80         17.9 ± 8.40         <0.001	hsCRP (mg/L)	2.10 (1.00-7.60)	4.30 (1.70-8.70)	0.024
TNF- $\alpha$ (pg/mL)       12.8 (11.7–17.0)       14.3 (12.5–16.5)       0.469         TGF- $\beta$ (pg/mL)       179 (1.00–680)       172 (42.2–460)       0.872         HGS (kg)       24.8 ± 9.80       17.9 ± 8.40       <0.001	IL-6 (pg/mL)	6.80 (4.60-10.7)	9.40 (6.30-16.5)	0.026
TGF -β (pg/mL)         179 (1.00-680)         172 (42.2-460)         0.872           HGS (kg)         24.8 ± 9.80         17.9 ± 8.40         <0.001	IL-1 $\beta$ (pg/mL)	5.00 (5.00-7.20)	5.00 (5.00-7.50)	0.962
HGS (kg)         24.8 ± 9.80         17.9 ± 8.40         <0.001           Low-HGS [n (%)]         22 (61.1)         66 (89.2)         0.001           MAMC (cm)         21.3 ± 3.00         21.9 ± 3.50         0.383           Lean mass (kg)         46.4 ± 9.40         45.6 ± 10.4         0.684           Fat mass (kg)         13.4 ± 4.80         16.8 ± 6.60         0.008           ASMI (kg/m²)         6.80 ± 1.00         6.80 ± 1.20         0.752	TNF-α (pg/mL)	12.8 (11.7–17.0)	14.3 (12.5–16.5)	0.469
Low-HGS [n (%)]         22 (61.1)         66 (89.2)         0.001           MAMC (cm)         21.3 ± 3.00         21.9 ± 3.50         0.383           Lean mass (kg)         46.4 ± 9.40         45.6 ± 10.4         0.684           Fat mass (kg)         13.4 ± 4.80         16.8 ± 6.60         0.008           ASMI (kg/m²)         6.80 ± 1.00         6.80 ± 1.20         0.752	TGF- $\beta$ (pg/mL)	179 (1.00–680)	172 (42.2-460)	0.872
MAMC (cm)         21.3 ± 3.00         21.9 ± 3.50         0.383           Lean mass (kg)         46.4 ± 9.40         45.6 ± 10.4         0.684           Fat mass (kg)         13.4 ± 4.80         16.8 ± 6.60         0.008           ASMI (kg/m²)         6.80 ± 1.00         6.80 ± 1.20         0.752	HGS (kg)	24.8 ± 9.80	$17.9 \pm 8.40$	< 0.001
Lean mass (kg)         46.4 ± 9.40         45.6 ± 10.4         0.684           Fat mass (kg)         13.4 ± 4.80         16.8 ± 6.60         0.008           ASMI (kg/m²)         6.80 ± 1.00         6.80 ± 1.20         0.752	Low-HGS [n (%)]	22 (61.1)	66 (89.2)	0.001
Fat mass (kg)         13.4 ± 4.80         16.8 ± 6.60         0.008           ASMI (kg/m²)         6.80 ± 1.00         6.80 ± 1.20         0.752	MAMC (cm)	21.3 ± 3.00	21.9 ± 3.50	0.383
ASMI (kg/m <sup>2</sup> ) 6.80 ± 1.00 6.80 ± 1.20 0.752	Lean mass (kg)	$46.4\pm9.40$	$45.6\pm10.4$	0.684
	Fat mass (kg)	13.4 ± 4.80 16.8 ± 6.60		0.008
Sarcopenia [n (%)] 13 (36.1) 26 (35.1) 0.920	ASMI (kg/m²)	6.80 ± 1.00	6.80 ± 1.20	0.752
	Sarcopenia [n (%)]	13 (36.1)	26 (35.1)	0.920

PCS, Physical Component Summary; BMI, body mass index; BUN, blood urea nitrogen; Kt/V, dialysis efficiency index; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; IL-1 $\beta$ , interleukin-1 $\beta$ ; TNF- $\alpha$ , tumor necrosis factor- $\alpha$ ; TGF- $\beta$ , transforming growth factor- $\beta$ ; HGS, hand grip strength; MAMC, mid-arm muscle circumference; ASMI, appendicular skeletal muscle index. Continuous variables are expressed as mean  $\pm$  standard deviation or median with interquartile range in case of nonnormally distributed data, and categorical variables are expressed as percentages.

<sup>†</sup>Patients were divided into the 2 groups by whether PCS  $\geq$  50.

<sup>t</sup>Obtained from two-sample t-test, Mann–Whitney U test, or chi-square test as appropriate. <sup>§</sup>Other: IgA nephropathy, membranous nephropathy, drug-induced nephropathy.

specific emphasis on muscle strength, within the Chinese hemodialysis patient. Our findings suggest that HGS was independently associated with a better quality of life, predominantly reflected in the PCS score TABLE 2 Comparison of clinical characteristics of the high- and low-MCS groups.

Variables	High-MCS <sup>†</sup> n = 94	Low-MCS <sup>†</sup> n = 16	$p^{\dagger}$
Age (years)	64.2 ± 13.2	$62.1 \pm 12.1$	0.546
Women [n (%)]	35 (37.2)	5 (31.2)	0.646
BMI, (kg/m <sup>2</sup> )	$23.2\pm3.80$	$21.7\pm2.60$	0.142
Dialysis vintage (months)	24.5 (11.0-51.3)	41.0 (16.0-72.8)	0.214
Cause of end-stage renal disease [n (%)]			0.680
Diabetic nephropathy	35 (37.2)	4 (25.0)	
Hypertensive nephropathy	12 (12.8)	2 (12.4)	
Polycystic kidney disease	3 (3.20)	1 (6.30)	
Unknown causes	34 (36.2)	8 (50.0)	
Other <sup>s</sup>	10 (10.6)	1 (6.30)	
Diabetes mellitus [n (%)]	49 (52.1)	7 (43.8)	0.535
BUN (mmol/L)	27.3 (23.6–32.3)	29.0 (23.7-31.8)	0.845
Creatinine (µmol/L)	985 ± 313	1,015 ± 152	0.559
Kt/V	1.30 (1.20–1.50)	1.30 (1.20-1.60)	0.665
Serum phosphorus			
(mmol/L)	2.10 (1.80-2.50)	2.50 (1.90-2.90)	0.168
Hemoglobin (g/L)	96.6 ± 16.8	99.0 ± 17.1	0.594
Albumin (g/L)	37.1 ± 3.30	37.4 ± 3.20	0.689
Prealbumin (mg/L)	329 ± 70.0	336 ± 54.9	0.706
Triglyceride (mmol/L)	$2.20 \pm 1.70$	$1.50 \pm 0.60$	0.125
Total cholesterol (mmol/L)	$4.60 \pm 1.10$	$4.00\pm0.80$	0.034
hsCRP (mg/L)	3.20 (1.60-8.60)	2.30 (1.10-9.40)	0.486
IL-6 (pg/mL)	8.80 (5.80-17.1)	8.80 (6.30-12.6)	0.888
IL-1β, (pg/mL)	5.00 (5.00-7.40)	5.00 (5.00-9.50)	0.666
TNF- $\alpha$ , (pg/mL)	14.2 (12.4–16.7)	12.4 (11.4–15.0)	0.161
TGF- $\beta$ , (pg/mL)	157 (1.00–434)	276 (142–677)	0.221
HGS, (kg)	20.3 ± 9.80	$19.8\pm7.10$	0.860
Low-HGS, [n (%)]	75 (79.8)	13 (81.3)	1.000
MAMC, (cm)	21.9 ± 3.50	$20.5\pm2.30$	0.117
Lean mass, (kg)	$45.8 \pm 10.4$	$46.2\pm7.80$	0.908
Fat mass, (kg)	$15.9 \pm 6.50$	$14.1\pm4.10$	0.304
ASMI, (kg/m²)	6.80 ± 1.20	$6.80\pm0.80$	0.797
Sarcopenia [n (%)]	32 (34.0)	7 (43.8)	0.453

MCS, Mental Component Summary; BMI, body mass index; BUN, blood urea nitrogen; Kt/V, dialysis efficiency index; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; IL-1 $\beta$ , interleukin-1 $\beta$ ; TNF- $\alpha$ , tumor necrosis factor- $\alpha$ ; TGF- $\beta$ , transforming growth factor- $\beta$ ; HGS, hand grip strength; MAMC, mid-arm muscle circumference; ASMI, appendicular skeletal muscle index. Continuous variables are expressed as mean  $\pm$  standard deviation or median with interquartile range in case of nonnormally distributed data, and categorical variables are expressed as percentages.

<sup>†</sup>Patients were divided into the 2 groups by whether MCS  $\geq$  50.

<sup>‡</sup>Obtained from two-sample t-test, Mann–Whitney U test, or chi-square test as appropriate. <sup>§</sup>Other: IgA nephropathy, membranous nephropathy, drug-induced nephropath.

of the SF-36. However, no significant correlation was found in the MCS domain.

In our study, the mean SF-36 PCS was 43.8 and the mean SF-36 MCS was 57.3, which closely aligns with previous study's findings of PCS 46.3 and MCS 55.1 in Romania (30). However, our study exhibits



substantial discrepancies when compared to research conducted in Russia (31). Studies from different countries have shown that there are differences in HRQoL among ESRD patients treated with hemodialysis. A study involving MHD patients from three continents demonstrated significant variations in HRQoL across various countries and regions (11). Patients in the United States had the highest MCS scores, and Japanese patients reported better physical functioning than those in the United States or Europe. PCS scores across various studies ranged from 33.1 to 46.3, while MCS scores ranged from 43.2 to 55.1 (11, 30, 31). The possible reasons for the existence of these differences are potentially due to variations in sample size, demographic characteristics, comorbidities, social support, and dialysis duration.

In the present study, the low PCS group was associated with lower values for parameters related to muscle strength, such as HGS, older age, and lower creatinine levels, as well as with higher levels of inflammation, such as hsCRP and IL-6, and higher levels of TC and body fat mass. The low-PCS group exhibited a significantly higher mean age compared to the high-PCS group. It may be due to a decrease in physical activity levels with aging, and a reduction in social activities as well. Fat mass in the high-PCS groups was lower than the low-PCS group. One possible explanation is that individuals in the high-PCS group tend to participate in more social activities and exhibit a higher level of physical activity. Increasing physical activity levels has been shown to be advantageous for promoting an increase in lean body mass and a decrease in body fat mass. Compared to the high-PCS group, the low-PCS group had higher inflammatory markers (IL-6 and hsCRP). This phenomenon may be mediated by the change in body fat composition. As mentioned above, MHD patients in the low-PCS group had higher fat mass, which is associated with a redistribution of fat depots, shifting from subcutaneous locations to more harmful ectopic locations (32-35). This redistribution results in obesity, particularly visceral fat deposits, and lipid spillover into muscle (36-38). This fat deposition shifts fat into infiltrating skeletal muscle as intermuscular adipose tissue, which releases a host of proinflammatory cytokines, such as interleukin-6 (IL-6), onto muscle fibers, resulting in local inflammation within the muscle (39). Our findings indicated that body fat mass, hsCRP and IL-6 may also serve as one of the indicators for assessing HRQoL in hemodialysis patients. In addition, the results showed that the high-PCS group had lower TC levels. Possible explanations include the fact that, for people in the high-PCS group, they tend to be more active and socially inclined, which may contribute to keep better body composition and blood lipid levels. The research by Lonardo et al. suggested that changes in skeletal muscle mass could have a role in worsening lipid profile (40).

As for the MCS groups, the high-MCS group exhibited higher TC levels. The differences in TC levels between the groups remain unclear. However, one study conducted in Chinese centenarians found that lipid profile was positively associated with the HRQoL (41). These findings warrant further investigation to elucidate the relationship between MCS and TC levels in MHD patient.

In this study, the mean HGS measurement was  $19.3 \pm 9.50$  kg, consistent with other studies on dialysis patients (42, 43). The multivariate logistic regression model revealed that only HGS was significantly associated with the SF-36 PCS scores, indicating that muscle strength determined by handgrip, rather than body composition (fat mass and ASMI), could be an independent factor that lowers

TABLE 3 Demographic, biochemical and anthropometric parameters of the study participants (n = 110).

Variables	Mean <u>+</u> SD, Median [IQR] or n (%) <sup>†</sup>		
Age (years)	63.9 ± 13.0		
Women [n (%)]	40 (36.4)		
BMI (kg/m <sup>2</sup> )	23.0 ± 3.60		
Dialysis vintage (months)	25.5 (12.0–52.3)		
Cause of end-stage renal disease [n (%)]			
Diabetic nephropathy	39 (35.5)		
Hypertensive nephropathy	14 (12.7)		
Polycystic kidney disease	4 (3.60)		
Unknown causes	42 (38.2)		
Other <sup>‡</sup>	11 (10.0)		
Diabetes mellitus [n (%)]	56 (50.9)		
BUN (mmol/L)	27.5 (23.7–32.0)		
Creatinine (µmol/L)	989 ± 294		
Kt/V	1.30 (1.20–1.50)		
Serum phosphorus (mmol/L)	2.20 (1.80-2.60)		
Hemoglobin (g/L)	96.9 ± 16.8		
Albumin (g/L)	37.1 ± 3.20		
Prealbumin (mg/L)	330 ± 67.7		
Triglyceride (mmol/L)	2.10 ± 1.60		
Total cholesterol (mmol/L)	4.50 ± 1.10		
hsCRP (mg/L)	3.00 (1.50-8.60)		
IL-6 (pg/mL)	8.80 (5.90-15.6)		
IL-1β (pg/mL)	5.00 (5.00-7.40)		
TNF-α (pg/mL)	14.2 (12.3–16.6)		
TGF-β (pg/mL)	178 (17.8–530)		
HGS (kg)	19.3 ± 9.50		
Men	23.7 ± 9.60		
Women	14.3 ± 5.30		
Low-HGS [n (%)]	88 (80.0)		
MAMC (cm)	21.7 ± 3.40		
Lean mass (kg)	45.9 ± 10.0		
Fat mass (kg)	15.6 ± 6.20		
ASMI (kg/m²)			
Men	7.20 ± 0.90		
Women	6.20 ± 1.20		
Low-ASMI [n (%)]	39 (35.5)		
Sarcopenia [n (%)]	39 (35.5)		
SF-36	628 (577–689)		
PCS	43.8 ± 9.50		
MCS	57.3 ± 8.80		

n, number of participants; SD, standard deviation; IQR, interquartile range; %, percentage of participants; BMI, body mass index; BUN, blood urea nitrogen; Kt/V, dialysis efficiency index; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α; TGF-β, transforming growth factor-β; HGS, handgrip strength; MAMC, mid-arm muscle circumference; ASMI, appendicular skeletal muscle index; SF-36, Study Short Form 36; PCS, Physical Component Summary; MCS, Mental Component Summary. 'Continuous variables are expressed as mean ± standard deviation or median with interquartile range in case of nonnormally distributed data, and categorical variables are expressed as percentages.

<sup>†</sup>Other: IgA nephropathy, membranous nephropathy, drug-induced nephropathy.

physical health of the HRQoL in MHD patients. In previous studies on hemodialysis patients, Maria et al. found that there was no association between sarcopenia and HRQoL, but the components of sarcopenia (handgrip strength and gait speed) showed a correlation with the physical domain of HRQoL (22). Giglio et al. demonstrated that the group with low muscle strength had lower scores in the SF-36 domains, a finding not observed in the group of low muscle mass (23). Similarly, Tsekoura et al. suggested that HGS was significantly correlated with quality of life in hemodialysis patients (42). The associations between muscle strength and HRQoL have also been reported in other populations, such as healthy adults, patients with osteoporosis, cancer survivors, systemic lupus erythematosus patients and spinal disorders patients, suggesting that muscle strength rather than skeletal muscle mass might affect HRQoL (44-48). The mechanism underlying the positive association between muscle strength and HRQoL reported in the aforementioned studies is hypothesized to be mediated by physical activity. Physical inactivity in MHD patients can cause muscle weakness, declines in physical functioning and reduction of atrophic fiber number. The loss of motor neurons leads to an increase in the size of remaining motor units, concurrent with a greater preservation of type I muscle fibers. This results in the preservation of muscle mass with a relatively smaller proportion of type II fibers, thereby contributing to reduced muscle strength (49). Chen et al. conducted a randomized controlled trial in which MHD patients underwent intradialytic low-intensity strength training or stretching exercises (control group) (50). The results showed that compared with the control group, the strength training group showed significant improvements in knee extensor strength and HRQoL domains such as leisure time, physical activity, and selfreported physical function and disability in activities of daily living. Silva et al. also found that supervised physical therapy during hemodialysis sessions improved knee extensor muscle strength, leading to benefits in activities of daily living and HRQoL (51). The current findings suggest that even at lower training intensities, most MHD patients increase muscle strength, minimizing the negative impact of a sedentary lifestyle (23, 51, 52). Maintaining or promoting muscle strength through exercise is crucial for the HRQoL of patients undergoing MHD.

Our results indicated that high HGS was independently correlated with a better quality of life, primarily in the PCS domain. However, no significant correlation was found in the MCS domain. These results align with some prior studies conducted on older populations, (53, 54) but only partially agree with other investigations. In MHD patients and community-dwelling nonagenarians, several studies have substantiated the correlation between HGS and both physical and mental health (23). Sayer et al. reported a correlation between reduced grip strength and a higher prevalence of poor SF-36 score in general health, physical activity and mental health among younger individuals (20). In contrast, Wang et al.'s study did not demonstrate a correlation between muscle strength and PCS or MCS domain scores in MHD patients (55). The discrepancies observed in these studies could be attributed to several factors: (a) Variations in muscle strength measurement methods, such as focusing on ankle dorsiflexion strength (reflecting lower limb muscle strength) or grip strength (primarily reflecting upper limb muscle strength); (b) Inconsistencies in the scales used to measure HRQoL, including the SF-36, EuroQol-5 Dimensions, and disease-specific scales; (c) Diversity in study populations, encompassing age, race, comorbidities, and other demographic factors, which may contribute to differing outcomes. TABLE 4 Results of multivariate binary logistic regression analyses of low-PCS (dependent variable) according to related HGS indicators (independent variables).

	Model1 <sup>†</sup>	Model2 <sup>‡</sup>	Model3 <sup>§</sup>	Model4 <sup>¶</sup>	Model5 <sup>††</sup>
HGS (kg) as a con	HGS (kg) as a continuous variable				
Odds ratio	0.917	0.917	0.917	0.917	0.917
95%CI	0.871-0.966	0.871-0.966	0.871-0.966	0.871-0.966	0.871-0.966
<i>p</i> value	0.001	0.001	0.001	0.001	0.001
HGS (normal/Low HGS) as a categorical variable					
Normal-HGS	Ref	Ref	Ref	Ref	Ref
Low-HGS					
Odds ratio	5.25	5.25	5.36	5.36	5.36
95%CI	1.94-14.2	1.94-14.2	1.89–15.2	1.89–15.2	1.89–15.2
<i>p</i> value	0.001	0.001	0.002	0.002	0.002

PCS, Physical Component Summary; HGS, handgrip strength; CI, confidence interval; TC, total cholesterol; hsCRP, high-sensitivity C-reactive protein.

<sup>†</sup>Model 1: Unadjusted.

\*Model 2: Adjusted for age and sex.

<sup>§</sup>Model 3: Adjusted for model2 plus fat mass and ASMI.

Model 4: Adjusted for model3 plus creatinine, TC and hsCRP.

<sup>††</sup>Model 5: Adjusted for model4 plus albumin.

Therefore, further research is necessary to explore the relationship between upper and lower limb muscle strength and HRQoL in hemodialysis patients, with a specific focus on prospective and interventional studies.

In summary, this study found that HGS, body fat mass, IL-6, hsCRP and TC were associated with HRQoL in a univariate analysis. Multivariate logistic regression model suggested that HGS may serve as a robust predictor of HRQoL in patients undergoing MHD. However, further research is warranted to validate these findings. The major strength of our study is that it firstly analyzed the relationship between HGS and HRQoL in Chinese patients undergoing MHD. Moreover, prior research has suggested that multiple factors may impact HRQoL scores and muscle health in MHD patients (43, 56-58). We considered potential confounders-age, sex, fat mass, ASMI, creatinine and TC levels, as well as inflammatory markers such as hsCRP and nutritional indicators such as albumin-thus bolstering the reliability of our results. The study faced several limitations. Firstly, due to its cross-sectional design, the study cannot establish any cause-effect relationships between muscle strength and HRQoL. Secondly, the analysis excluded certain sociodemographic variables such as education level, marital status, and living arrangements, as well as factors like depression and sleep quality. These omissions may have affected the potential for robust correlations between muscle strength and HRQoL, including dietary intake and nutritional status, which are also known to affect the quality of life of MHD patients (18, 56, 59). Furthermore, the participants of this study were selected from a single hemodialysis center using a convenience sampling approach. Future research aims to enhance the robustness of the findings by increasing the sample size, adopting more rigorous sampling methods, and conducting multi-center studies to explore the relationship between muscle strength and quality of life.

## Conclusion

In conclusion, HGS might represent a simple and reliable screening tool for assessing HRQoL, particularly in relation to physical health, in patients undergoing MHD. The management of muscle strength may play a pivotal role in improving HRQoL in MHD patients.

### Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

### **Ethics statement**

The studies involving humans were approved by Ethics Committee of Guangzhou Red Cross Hospital, Jinan University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

### Author contributions

CL: Data curation, Investigation, Methodology, Writing – original draft, Formal analysis. XP: Data curation, Investigation, Writing – original draft. SX: Investigation, Writing – original draft. JH: Investigation, Writing – original draft. XZ: Investigation, Methodology, Writing – review & editing. LW: Data curation, Formal analysis, Writing – original draft. JQ: Data curation, Formal analysis, Writing – original draft. RT: Methodology, Supervision, Writing – review & editing.

## Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Guangzhou Municipal Health Science and Technology Project under Grant (20221A011017); Guangzhou Municipal Science and Technology Bureau Project under Grant (SL2022A03J00165); Guangzhou Municipal Health Science; Technology Project under Grant (20231A010017) and Guangzhou Science and Technology Plan Project (2023A03J0516).

### Acknowledgments

The authors are indebted to all the nephrologists and nurses in our hemodialysis center for their excellent management of hemodialysis patients. The authors also thank all study participants and staff involved in the cross-sectional study.

### References

1. Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. *Clin J Am Soc Nephrol.* (2009) 4:1057–64. doi: 10.2215/CJN.00430109

2. Wight JP, Edwards L, Brazier J, Walters S, Payne JN, Brown CB. The SF36 as an outcome measure of services for end stage renal failure. *Qual Health Care*. (1998) 7:209–21. doi: 10.1136/qshc.7.4.209

3. Baral S, Kaphle HP. Health-related quality of life among menopausal women: a cross-sectional study from Pokhara. *Nepal PLoS One.* (2023) 18:e0280632. doi: 10.1371/journal.pone.0280632

4. Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis outcomes and practice patterns study (DOPPS). *Kidney Int.* (2003) 64:339–49. doi: 10.1046/j.1523-1755.2003.00072.x

5. Lowrie EG, Curtin RB, LePain N, Schatell D. Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients. *Am J Kidney Dis.* (2003) 41:1286–92. doi: 10.1016/S0272-6386(03)00361-5

6. Lopez Revuelta K, Garcia Lopez FJ, de Alvaro MF, Alonso J. Perceived mental health at the start of dialysis as a predictor of morbidity and mortality in patients with end-stage renal disease (CALVIDIA study). *Nephrol Dial Transplant*. (2004) 19:2347–53. doi: 10.1093/ndt/gfh392

 Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT. Predictors of poor outcome in chronic dialysis patients: the Netherlands cooperative study on the adequacy of Dialysis. The NECOSAD study group. *Am J Kidney Dis.* (2000) 35:69–79. doi: 10.1016/S0272-6386(00)70304-0

8. Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC. The association between mental health, physical function, and hemodialysis mortality. *Kidney Int.* (2003) 63:1843–51. doi: 10.1046/j.1523-1755.2003.00931.x

9. Apolone G, Mosconi P. Review of the concept of quality of life assessment and discussion of the present trend in clinical research. *Nephrol Dial Transplant*. (1998) 13:65–9. doi: 10.1093/ndt/13.suppl\_1.65

10. Gomez-Besteiro MI, Santiago-Perez MI, Alonso-Hernandez A, Valdes-Canedo F, Rebollo-Alvarez P. Validity and reliability of the SF-36 questionnaire in patients on the waiting list for a kidney transplant and transplant patients. *Am J Nephrol.* (2004) 24:346–51. doi: 10.1159/000079053

11. Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, et al. Health-related quality of life among dialysis patients on three continents: the Dialysis outcomes and practice patterns study. *Kidney Int.* (2003) 64:1903–10. doi: 10.1046/j.1523-1755.2003.00289.x

12. Domanski M, Ciechanowski K. Sarcopenia: a major challenge in elderly patients with end-stage renal disease. *J Aging Res.* (2012) 2012:754739:1–12. doi: 10.1155/2012/754739

13. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. (2020) 21:300–307.e2. doi: 10.1016/j.jamda.2019.12.012

14. Lamarca F, Carrero JJ, Rodrigues JC, Bigogno FG, Fetter RL, Avesani CM. Prevalence of sarcopenia in elderly maintenance hemodialysis patients: the impact of different diagnostic criteria. *J Nutr Health Aging.* (2014) 18:710–7. doi: 10.1007/s12603-014-0505-5

15. Workeneh BT, Mitch WE. Review of muscle wasting associated with chronic kidney disease. Am J Clin Nutr. (2010) 91:1128S-32S. doi: 10.3945/ajcn.2010.28608B

16. Yamada M, Kimura Y, Ishiyama D, Nishio N, Abe Y, Kakehi T, et al. Differential characteristics of skeletal muscle in community-dwelling older adults. *J Am Med Dir Assoc.* (2017) 18:807.e9–e16. doi: 10.1016/j.jamda.2017.05.011

### **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

17. Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. *J Gerontol A Biol Sci Med Sci.* (2006) 61:72–7. doi: 10.1093/gerona/61.1.72

18. Laudisio A, Giovannini S, Finamore P, Loreti C, Vannetti F, Coraci D, et al. Muscle strength is related to mental and physical quality of life in the oldest old. *Arch Gerontol Geriatr.* (2020) 89:104109. doi: 10.1016/j.archger.2020.104109

19. Manrique-Espinoza B, Salinas-Rodriguez A, Rosas-Carrasco O, Gutierrez-Robledo LM, Avila-Funes JA. Sarcopenia is associated with physical and mental components of health-related quality of life in older adults. *J Am Med Dir Assoc.* (2017) 18:636.e1–5. doi: 10.1016/j.jamda.2017.04.005

20. Sayer AA, Syddall HE, Martin HJ, Dennison EM, Roberts HC, Cooper C. Is grip strength associated with health-related quality of life? Findings from the Hertfordshire cohort study. Age Ageing. (2006) 35:409–15. doi: 10.1093/ageing/afl024

21. Kaymaz D, Candemir IC, Ergun P, Demir N, Tasdemir F, Demir P. Relation between upper-limb muscle strength with exercise capacity, quality of life and dyspnea in patients with severe chronic obstructive pulmonary disease. *Clin Respir J.* (2018) 12:1257–63. doi: 10.1111/crj.12659

22. Celoto BRB, Marin FA, Spexoto MCB. Assessment of the components of sarcopenia and quality of life perceived of individuals on hemodialysis. *Rev Bras Enferm.* (2023) 76:e20220677. doi: 10.1590/0034-7167-2022-0677

23. Giglio J, Kamimura MA, Lamarca F, Rodrigues J, Santin F, Avesani CM. Association of Sarcopenia with Nutritional Parameters, quality of life, hospitalization, and mortality rates of elderly patients on hemodialysis. *J Ren Nutr.* (2018) 28:197–207. doi: 10.1053/j.jrn.2017.12.003

24. Li L, Wang HM, Shen Y. Chinese SF-36 health survey: translation, cultural adaptation, validation, and normalisation. *J Epidemiol Community Health*. (2003) 57:259–63. doi: 10.1136/jech.57.4.259

25. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Med Care*. (1993) 31:247–63. doi: 10.1097/00005650-199303000-00006

26. Lam CL, Tse EY, Gandek B, Fong DY. The SF-36 summary scales were valid, reliable, and equivalent in a Chinese population. *J Clin Epidemiol.* (2005) 58:815–22. doi: 10.1016/j.jclinepi.2004.12.008

27. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. *J Am Soc Nephrol.* (1993) 4:1205–13. doi: 10.1681/ASN.V451205

28. Heymsfield SB, McManus C, Smith J, Stevens V, Nixon DW. Anthropometric measurement of muscle mass: revised equations for calculating bone-free arm muscle area. *Am J Clin Nutr.* (1982) 36:680–90. doi: 10.1093/ajcn/36.4.680

29. Slee A, McKeaveney C, Adamson G, Davenport A, Farrington K, Fouque D, et al. Estimating the prevalence of muscle wasting, weakness, and sarcopenia in hemodialysis patients. *J Ren Nutr.* (2020) 30:313–21. doi: 10.1053/j.jrn.2019.09.004

30. Seica A, Segall L, Verzan C, Vaduva N, Madincea M, Rusoiu S, et al. Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric study. *Nephrol Dial Transplant.* (2009) 24:626–9. doi: 10.1093/ndt/gfn506

31. Vasilieva IA. Quality of life in chronic hemodialysis patients in Russia. *Hemodial Int.* (2006) 10:274-8. doi: 10.1111/j.1542-4758.2006.00108.x

32. Ebner N, Sliziuk V, Scherbakov N, Sandek A. Muscle wasting in ageing and chronic illness. *ESC Heart Fail*. (2015) 2:58–68. doi: 10.1002/ehf2.12033

33. Hughes VA, Roubenoff R, Wood M, Frontera WR, Evans WJ, Fiatarone Singh MA. Anthropometric assessment of 10-y changes in body composition in the elderly. *Am J Clin Nutr.* (2004) 80:475–82. doi: 10.1093/ajcn/80.2.475

34. Ponti F, Santoro A, Mercatelli D, Gasperini C, Conte M, Martucci M, et al. Aging and imaging assessment of body composition: from fat to facts. *Front Endocrinol (Lausanne)*. (2019) 10:861. doi: 10.3389/fendo.2019.00861

35. Raguso CA, Kyle U, Kossovsky MP, Roynette C, Paoloni-Giacobino A, Hans D, et al. A 3-year longitudinal study on body composition changes in the elderly: role of physical exercise. *Clin Nutr.* (2006) 25:573–80. doi: 10.1016/j.clnu.2005.10.013

36. Addison O, Drummond MJ, LaStayo PC, Dibble LE, Wende AR, McClain DA, et al. Intramuscular fat and inflammation differ in older adults: the impact of frailty and inactivity. *J Nutr Health Aging*. (2014) 18:532–8. doi: 10.1007/s12603-014-0019-1

37. Akazawa N, Kishi M, Hino T, Tsuji R, Tamura K, Hioka A, et al. Intramuscular adipose tissue in the quadriceps is more strongly related to recovery of activities of daily living than muscle mass in older inpatients. *J Cachexia Sarcopenia Muscle*. (2021) 12:891–9. doi: 10.1002/jcsm.12713

38. Conte M, Martucci M, Sandri M, Franceschi C, Salvioli S. The dual role of the pervasive "fattish" tissue remodeling with age. *Front Endocrinol (Lausanne)*. (2019) 10:114. doi: 10.3389/fendo.2019.00114

39. Wang T. Searching for the link between inflammaging and sarcopenia. *Ageing Res Rev.* (2022) 77:101611. doi: 10.1016/j.arr.2022.101611

40. Lonardo MS, Guida B, Cacciapuoti N, Chiurazzi M, Pacella D, Cataldi M. Evidence that skeletal muscles modulate HDL-cholesterol in metabolic healthy young adults. *Nutrients*. (2024) 16:1110. doi: 10.3390/nu16081110

41. Wang S, Yang S, Jia W, Cao W, Han K, Liu M, et al. Relationships of lipids profile with health-related quality of life in Chinese centenarians. *J Nutr Health Aging*. (2020) 24:404–11. doi: 10.1007/s12603-020-1340-5

42. Tsekoura M, Drousiotis G, Avgeri M, Billis E, Katsoulaki M, Kastrinis A, et al. Hand grip Strength in patients on hemodialysis: an observational study. *Adv Exp Med Biol.* (2021) 1337:59–64. doi: 10.1007/978-3-030-78771-4\_7

43. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. *Kidney Int.* (1998) 53:773–82. doi: 10.1046/j.1523-1755.1998.00812.x

44. Hart PD. Grip Strength and health-related quality of life in U.S. Adult Males J Lifestyle Med. (2019) 9:102-10. doi: 10.15280/jlm.2019.9.2.102

45. Park HJ, Han B, Chang SY, Kang SH, Lee DW, Strength G. Osteoporosis, and quality of life in middle-aged and older adults. *Medicina (Kaunas)*. (2023) 59:148. doi: 10.3390/medicina59122148

46. Kim J, Kang S, Kim D, Kang H. Associations of physical activity and handgrip Strength with health-related quality of life in older Korean Cancer survivors. *Cancers* (*Basel*). (2022) 14:6067. doi: 10.3390/cancers14246067

47. Sumantri S, Seto E, Rengganis I. Muscle strength, not muscle mass, determines the health-related quality of life in Indonesian women with systemic lupus erythematosus. *Lupus Sci Med.* (2023) 10:e001025. doi: 10.1136/lupus-2023-001025

48. Tanaka Y, Miyagi M, Inoue G, Hori Y, Inage K, Murata K, et al. Muscle strength rather than appendicular skeletal muscle mass might affect spinal sagittal alignment, low back pain, and health-related quality of life. *Sci Rep.* (2023) 13:9894. doi: 10.1038/ s41598-023-37125-w

49. Andersen JL. Muscle fibre type adaptation in the elderly human muscle. *Scand J Med Sci Sports.* (2003) 13:40–7. doi: 10.1034/j.1600-0838.2003.00299.x

50. Chen JL, Godfrey S, Ng TT, Moorthi R, Liangos O, Ruthazer R, et al. Effect of intra-dialytic, low-intensity strength training on functional capacity in adult haemodialysis patients: a randomized pilot trial. *Nephrol Dial Transplant.* (2010) 25:1936–43. doi: 10.1093/ndt/gfp739

51. Silva SF, Pereira AA, Silva WA, Simoes R. Physical therapy during hemodialyse in patients with chronic kidney disease. *J Bras Nefrol.* (2013) 35:170–6. doi: 10.5935/0101-2800.20130028

52. Avesani CM, Trolonge S, Deleaval P, Baria F, Mafra D, Faxen-Irving G, et al. Physical activity and energy expenditure in haemodialysis patients: an international survey. *Nephrol Dial Transplant*. (2012) 27:2430–4. doi: 10.1093/ndt/gfr692

53. Haider S, Luger E, Kapan A, Titze S, Lackinger C, Schindler KE, et al. Associations between daily physical activity, handgrip strength, muscle mass, physical performance and quality of life in prefrail and frail community-dwelling older adults. *Qual Life Res.* (2016) 25:3129–38. doi: 10.1007/s11136-016-1349-8

54. Takata Y, Ansai T, Soh I, Awano S, Yoshitake Y, Kimura Y, et al. Quality of life and physical fitness in an 85-year-old population. *Arch Gerontol Geriatr.* (2010) 50:272–6. doi: 10.1016/j.archger.2009.04.005

55. Wang AY, Sherrington C, Toyama T, Gallagher MP, Cass A, Hirakawa Y, et al. Muscle strength, mobility, quality of life and falls in patients on maintenance haemodialysis: a prospective study. *Nephrology (Carlton)*. (2017) 22:220–7. doi: 10.1111/ nep.12749

56. Germin-Petrovic D, Mesaros-Devcic I, Lesac A, Mandic M, Soldatic M, Vezmar D, et al. Health-related quality of life in the patients on maintenance hemodialysis: the analysis of demographic and clinical factors. *Coll Antropol.* (2011) 35:687–93.

57. Leal VO, Mafra D, Fouque D, Anjos LA. Use of handgrip strength in the assessment of the muscle function of chronic kidney disease patients on dialysis: a systematic review. *Nephrol Dial Transplant.* (2011) 26:1354–60. doi: 10.1093/ndt/gfq487

58. Wang AY, Sea MM, Ho ZS, Lui SF, Li PK, Woo J. Evaluation of handgrip strength as a nutritional marker and prognostic indicator in peritoneal dialysis patients. *Am J Clin Nutr.* (2005) 81:79–86. doi: 10.1093/ajcn/81.1.79

59. Pretto CR, Winkelmann ER, Hildebrandt LM, Barbosa DA, Colet CF, Stumm EMF. Quality of life of chronic kidney patients on hemodialysis and related factors. *Rev Lat Am Enfermagem*. (2020) 28:e3327. doi: 10.1590/1518-8345.3641.3327

# Glossary

HRQoL	Health-related quality of life
MHD	maintenance hemodialysis
SF-36	Short Form 36 Health Survey
PCS	Physical Component Summary
MCS	Mental Component Summary
HGS	handgrip strength
ESRD	end-stage renal disease
PF	physical functioning
RP	role limitations due to physical problems
BP	bodily pain
GH	general health
VT	vitality
SF	social functioning
RE	role limitations due to emotional problems
MH	mental health
AWGS	Asian Working Group for Sarcopenia
BUN	blood urea nitrogen
TC	total cholesterol
hsCRP	high-sensitivity C-reactive protein
IL-6	interleukin-6
IL-1 $\beta$	interleukin-1 $\beta$
TNF-α	tumor necrosis factor- $\alpha$
TGF- $\beta$	transforming growth factor- $\beta$
BMI	body mass index
TSF	triceps skinfold thickness
MAC	mid-upper arm circumference
МАМС	Mid-arm muscle circumference
ASM	appendicular skeletal muscle
ASMI	appendicular skeletal muscle index